Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

NASDAQ TTNP opened at $3.62 on Wednesday. Titan Pharmaceuticals has a 12 month low of $3.51 and a 12 month high of $14.80. The company’s 50 day moving average is $4.22 and its two-hundred day moving average is $5.35.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.